BOSTON SCIENTIFIC CORP 8-K

What Happened

• Boston Scientific Corporation held its 2026 Annual Meeting (virtual) on April 30, 2026 and filed an 8‑K on May 5, 2026. Stockholders approved amendments to the Third Restated Certificate of Incorporation (the “Charter Amendments”) to eliminate supermajority voting provisions, remove certain inoperative provisions, make clarifying/correcting changes, and to provide for exculpation of certain officers as permitted by Delaware law. The Company’s Fourth Restated Certificate of Incorporation became effective upon filing with the Delaware Secretary of State on May 5, 2026.
• All 10 director nominees were elected to one‑year terms (to hold office until the 2027 Annual Meeting). Other proposals passed included advisory approval of executive compensation (say‑on‑pay), ratification of Ernst & Young LLP as auditor, and an increase in shares reserved under the Employee Stock Purchase Plan.

Key Details

• Charter amendment to remove supermajority voting: For 1,189,271,431; Against 17,774,053; Abstain 3,348,909; Broker non‑votes 81,271,529. Fourth Restated Certificate filed May 5, 2026 (effective on filing).
• Exculpation of certain officers amendment: For 1,057,086,923; Against 150,458,633; Abstain 2,848,837; Broker non‑votes 81,271,529.
• Employee Stock Purchase Plan amendment (increase in shares reserved): Approved — For 1,205,130,032; Against 2,818,667; Abstain 2,445,694.
• Failed proposals: stockholder right to call a special meeting (25% ownership threshold) was not approved; a shareholder proposal to allow shareholders to call special meetings was also not approved (For 516,140,863; Against 689,739,605).

Why It Matters

• Removing supermajority provisions lowers the vote thresholds needed for certain charter changes, making corporate governance changes easier to approve in the future and increasing ordinary majority control for routine actions.
• Officer exculpation (as permitted under Delaware law) can limit the personal liability of certain officers in specified circumstances, which may affect management risk exposure.
• The ESPP increase supports employee equity compensation but may modestly increase share dilution over time.
• Rejection of shareholder proposals to expand special‑meeting rights shows limited investor support for broader shareholder-initiated meeting powers at this time.